

# Alex F Herrera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7020658/publications.pdf>

Version: 2024-02-01

124  
papers

5,323  
citations

159585

30  
h-index

95266

68  
g-index

124  
all docs

124  
docs citations

124  
times ranked

5207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	1.4	52
2	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	1.2	7
3	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
4	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	5.2	16
5	Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. <i>Clinical Cancer Research</i> , 2022, 28, 1294-1301.	7.0	12
6	Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. <i>Blood Advances</i> , 2022, 6, 1651-1660.	5.2	14
7	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	2.5	6
8	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	30
9	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. <i>Haematologica</i> , 2022, 107, 1214-1217.	3.5	5
10	Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post Autologous Stem Cell Transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.8	2
11	Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. <i>Blood</i> , 2022, 139, 3605-3616.	1.4	46
12	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	30.7	114
13	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	5.2	12
14	NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 322-334.	4.9	35
15	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	1.3	8
16	Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines. <i>Blood Advances</i> , 2022, 6, 5067-5071.	5.2	2
17	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 523-529.	1.2	7
18	Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2697-2708.	1.4	15

#	ARTICLE	IF	CITATIONS
19	PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e893-e897.	0.4	2
20	Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 1-7.	2.3	9
21	Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2021, 27, 1671-1680.	7.0	24
22	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 170-175.	0.4	17
23	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
24	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	5.2	28
25	How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. <i>Blood</i> , 2021, 138, 520-530.	1.4	4
26	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021, 138, 427-438.	1.4	109
27	Validation of the Double-Hit Gene Expression Signature (DLBCL90) in an Independent Cohort of Patients with Diffuse Large B-Cell Lymphoma of Germinal Center Origin. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 658-664.	2.8	3
28	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
29	Advances in Immunotherapy for Diffuse Large B Cell Lymphoma. <i>BioDrugs</i> , 2021, 35, 517-528.	4.6	1
30	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 911.e1-911.e7.	1.2	6
31	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
32	Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. <i>Blood Advances</i> , 2021, 5, 3387-3396.	5.2	17
33	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	5.2	24
34	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4762-4770.	5.2	17
35	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	1.2	7
36	Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 3563-3567.	5.2	5

#	ARTICLE	IF	CITATIONS
37	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	2.5	5
38	Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 5300-5311.	5.2	9
39	Barriers to achieving a cure in lymphoma. , 2021, 4, 965-983.		0
40	Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 739-739.	1.4	12
41	The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity. <i>Blood</i> , 2021, 138, 881-881.	1.4	1
42	Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. <i>Blood</i> , 2021, 138, 879-879.	1.4	3
43	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 133-133.	1.4	13
44	Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). <i>Blood</i> , 2021, 138, 1366-1366.	1.4	20
45	474â€¦Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress). , 2021, 9, A503-A503.		1
46	Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1407-1407.	1.4	1
47	Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 18-27.	4.1	46
48	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	1.6	488
49	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	1.6	216
50	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2401-2409.	1.4	92
51	Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. <i>Oncologist</i> , 2020, 25, 878-885.	3.7	28
52	Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. <i>British Journal of Haematology</i> , 2020, 191, 44-51.	2.5	19
53	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	1.4	62
54	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 962-972.	7.3	19

#	ARTICLE	IF	CITATIONS
55	Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 2238-2242.	7.2	6
56	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 1034-1044.	7.0	48
57	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	5.2	46
58	Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. <i>Oncologist</i> , 2020, 25, e993-e997.	3.7	7
59	Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleuce (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). <i>Blood</i> , 2020, 136, 49-49.	1.4	38
60	Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 19-20.	1.4	17
61	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 21-23.	1.4	16
62	Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 755-781.	4.9	94
63	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. <i>Blood</i> , 2020, 136, 40-41.	1.4	2
64	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	1.4	4
65	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2383-2387.	2.0	15
66	Noncellular Immune Therapies for Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 707-725.	2.2	7
67	The role of autologous stem cell transplantation in diffuse large B-cell lymphoma. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e33.	0.9	2
68	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
69	Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 477-486.	3.8	24
70	Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. <i>British Journal of Haematology</i> , 2019, 186, 255-262.	2.5	17
71	CAR T cells mimicking an aggressive lymphoma. <i>Blood</i> , 2019, 133, 1517-1517.	1.4	1
72	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	1.4	129

#	ARTICLE	IF	CITATIONS
73	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	7.1	44
74	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. <i>Blood Advances</i> , 2019, 3, 360-369.	5.2	92
75	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 287-292.	2.0	6
76	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	17.0	29
77	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1&2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	10.7	1,467
78	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019, 134, 238-238.	1.4	18
79	PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 239-239.	1.4	31
80	Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 759-759.	1.4	18
81	Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 4023-4023.	1.4	6
82	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. <i>Blood</i> , 2019, 134, 4075-4075.	1.4	10
83	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). <i>Blood</i> , 2019, 134, 764-764.	1.4	77
84	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	1.4	5
85	Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 240-240.	1.4	20
86	Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 4107-4107.	1.4	23
87	Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. <i>Blood</i> , 2019, 134, 4623-4623.	1.4	0
88	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4571-4571.	1.4	1
89	Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. <i>Blood</i> , 2019, 134, 5729-5729.	1.4	1
90	Genomic Characterization of Diffuse Large B-Cell Lymphoma Transformation from Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1486-1486.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Highlights in Lymphoma From the 60th American Society of Hematology Annual Meeting: Commentary. Clinical Advances in Hematology and Oncology, 2019, 17 Suppl 4, 20-23.	0.3	1
92	Highlights in Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting: Commentary. Clinical Advances in Hematology and Oncology, 2019, 17 Suppl 14, 21-23.	0.3	0
93	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2018, 131, 1183-1194.	1.4	276
94	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 514-520.	2.0	31
95	Where does PD-1 blockade fit in HL therapy?. Hematology American Society of Hematology Education Program, 2018, 2018, 213-220.	2.5	9
96	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematology and Oncology, 2018, 11, 87.	17.0	12
97	Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 452-468.e4.	0.4	32
98	Updates on Circulating Tumor DNA Assessment in Lymphoma. Current Hematologic Malignancy Reports, 2018, 13, 348-355.	2.3	14
99	Update on the role of brentuximab vedotin in classical Hodgkin lymphoma. Therapeutic Advances in Hematology, 2018, 9, 261-272.	2.5	6
100	Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). Blood, 2018, 132, 1635-1635.	1.4	9
101	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. Blood, 2018, 132, 1636-1636.	1.4	5
102	End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. Blood, 2018, 132, 4192-4192.	1.4	46
103	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. Blood, 2018, 132, 706-706.	1.4	3
104	Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". Blood, 2018, 132, 611-611.	1.4	7
105	New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Blood, 2018, 132, 346-346.	1.4	6
106	A Phase I/II Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). Blood, 2018, 132, 705-705.	1.4	10
107	Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Blood, 2018, 132, 1626-1626.	1.4	7
108	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. Blood, 2018, 132, 2892-2892.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. <i>Blood</i> , 2018, 132, 93-93.	1.4	0
110	Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab. <i>Blood</i> , 2018, 132, 2837-2837.	1.4	1
111	Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 293-302.	2.5	19
112	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1861-1869.	2.0	19
113	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.	1.6	152
114	Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. <i>Journal of Clinical Oncology</i> , 2017, 35, 3877-3887.	1.6	36
115	Double-Hit Lymphoma: Practicing in a Data-Limited Setting. <i>Journal of Oncology Practice</i> , 2016, 12, 239-240.	2.5	4
116	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 841-850.	2.5	47
117	Cyclin D1 expression in peripheral T-cell lymphomas. <i>Modern Pathology</i> , 2016, 29, 1306-1312.	5.5	15
118	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	1.6	212
119	Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1105-1105.	1.4	17
120	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	1.4	1
121	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	1.4	3
122	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.	1.4	26
123	Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. <i>Cancer</i> , 2014, 120, 1993-1999.	4.1	36
124	Cord Colitis: An Antibiotic-Responsive Colitis Syndrome Following Cord Blood Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 1270-1270.	1.4	0